Real-World Outcomes for Patients Treated with Ibrutinib for Relapsed/Refractory Mantle Cell Lymphoma in Denmark
Trine Trab(University of Copenhagen), Kirsten Grønbæk(University of Copenhagen), Thomas Stauffer Larsen(Odense University Hospital), Peter de Nully Brown(Copenhagen University Hospital), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Iman Chanchiri(Odense University Hospital), Ahmed Ludvigsen Al‐Mashhadi(Aarhus University Hospital), Simon Husby(Copenhagen University Hospital), Mikael Frederiksen(Hospital South West Jutland), Mette Johansen(Aarhus University Hospital), Jacob Haaber Christensen(Odense University Hospital), Michael Roost Clausen(Vejle Sygehus), Andriette C Desseau-Arp, Robert Schou Pedersen
Cited by 0
Related Papers
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337